Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Account Payables: 2017-2025

Historic Change in Account Payables for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to -$4.1 million.

  • Denali Therapeutics' Change in Account Payables rose 6.93% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year decrease of 46.42%. This contributed to the annual value of $1.4 million for FY2024, which is 40.89% down from last year.
  • Latest data reveals that Denali Therapeutics reported Change in Account Payables of -$4.1 million as of Q3 2025, which was down 256.74% from $2.6 million recorded in Q2 2025.
  • Denali Therapeutics' Change in Account Payables' 5-year high stood at $4.8 million during Q2 2023, with a 5-year trough of -$4.4 million in Q3 2024.
  • Its 3-year average for Change in Account Payables is -$22,182, with a median of $635,000 in 2024.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 626.11% in 2021, then slumped by 2,098.72% in 2022.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Change in Account Payables stood at -$78,000 in 2021, then plummeted by 2,098.72% to -$1.7 million in 2022, then dropped by 21.34% to -$2.1 million in 2023, then spiked by 161.80% to $1.3 million in 2024, then increased by 6.93% to -$4.1 million in 2025.
  • Its Change in Account Payables stands at -$4.1 million for Q3 2025, versus $2.6 million for Q2 2025 and -$2.6 million for Q1 2025.